CD19 and neoplasm: Although the CD19 antigen is not associated with solid tumors, its use provides homogenous unbiased 2xAARE-YB-regulated CAR-T cells that, in addition to mitigating experimental variations related to the use of two different tumor models, enable a clear comparison with constitutive CAR-T cells, which would have been otherwise difficult.